<DOC>
	<DOC>NCT01301573</DOC>
	<brief_summary>The purpose of this observational study is the long term follow-up of Parkinson's patients who participated in a clinical trial in which they received AAV-GAD gene transfer into the subthalamic nucleus (STN) region of the brain. Patients will be followed once a year for up to five (5) years. The study will monitor and evaluate the long term effects of AAV-GAD and provide long term safety information.</brief_summary>
	<brief_title>Long Term Follow-Up Study for rAAV-GAD Treated Subjects</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Participated in a clinical trial where they received AAVGAD Able to give informed consent to participate in the study Received Deep Brain Stimulation after receiving AAVGAD Received any experimental device in the brain after receiving AAVGAD Had any type of brain surgery after receiving AAVGAD Received any experimental therapy (drug or biologic) for Parkinson's disease or any other indication after receiving AAVGAD</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>